Trends in the choice of antiseizure medications in juvenile myoclonic epilepsy: A retrospective multi-center study from Turkey between 2010 and 2020

Basit Öğe Kaydı
dc.authoridKılıç, Betül/0000-0003-0884-2635
dc.authoridSerdaroglu, Esra/0000-0001-9925-0859
dc.authoridInce, Tugce/0000-0003-1520-3049
dc.authorscopusid56592297600
dc.authorscopusid54413097400
dc.authorscopusid57242576700
dc.authorscopusid57699214800
dc.authorscopusid56183749100
dc.authorscopusid42062598700
dc.authorscopusid13605183300
dc.authorwosidKılıç, Betül/ABS-2287-2022
dc.contributor.authorKilic, Betul
dc.contributor.authorSerdaroglu, Esra
dc.contributor.authorPolat, Burcin Gonullu
dc.contributor.authorInce, Tugce
dc.contributor.authorEsenulku, Gulnur
dc.contributor.authorTopcu, Yasemin
dc.contributor.authorSerdaroglu, Ayse
dc.date.accessioned2023-01-12T19:58:20Z
dc.date.available2023-01-12T19:58:20Z
dc.date.issued2022
dc.departmentN/A/Departmenten_US
dc.description.abstractPurpose:Valproic acid (VPA) is frequently used and effective in juvenile myoclonic epilepsy (JME). Recently, levetiracetam (LEV) has been suggested as a monotherapy in JME. This study aimed to evaluate antiseizure medication (ASM) use in patients with JME. Methods: Treatment choices in a total of 257 patients (age range 8-18 years, 152 girls, 105 boys) with JME diagnosed and treated between 2010 and 2020 were evaluated retrospectively. Seizure remission was defined as complete seizure control for at least 12 months. Results: Across the study period and entire patient group, VPA was most commonly chosen as the initial ASM (50.9%), followed by LEV (44.4%), and lamotrigine (4.7%). VPA was also the most frequent first choice in the subgroup of boys (73.3%), while LEV was the commonest first choice in girls (57.9%). The sex difference regarding the ASM of the first choice was statistically significant (p<0.001). While VPA was the most frequent initial ASM in the first 5 years of the study period (2010-2015,n = 66, 64%), LEV had taken over as the most popular first ASM in the last 5 years (n = 83, 53.9%, p = 0.005). The most frequent reasons for discontinuation were inefficacy for LEV and adverse effects for VPA (p= 0.001). During follow-up, 237 patients (92.2%) were seizure-free for at least 12 months, and 159 (61.9%) were also in electmgraphic remission. Seizure remission occurred earlier than electroencephalographic remission (p<0.001). Conclusion: This study revealed that LEV has become the most frequently chosen initial ASM in the treatment of JME. Although LEV appears to have a better adverse effect profile, VPA seems more likely to be effective in achieving seizure control.en_US
dc.identifier.doi10.1016/j.seizure.2022.05.005
dc.identifier.endpage53en_US
dc.identifier.issn1059-1311
dc.identifier.issn1532-2688
dc.identifier.pmid35594744en_US
dc.identifier.scopus2-s2.0-85130314617en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage48en_US
dc.identifier.urihttps://doi.org/10.1016/j.seizure.2022.05.005
dc.identifier.urihttps://hdl.handle.net/11454/76860
dc.identifier.volume99en_US
dc.identifier.wosWOS:000821623500005en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherW B Saunders Co Ltden_US
dc.relation.ispartofSeizure-European Journal of Epilepsyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectjuvenile myoclonic epilepsyen_US
dc.subjectvalproic aciden_US
dc.subjectlevetiracetamen_US
dc.subjectLevetiracetamen_US
dc.subjectValproateen_US
dc.subjectMonotherapyen_US
dc.subjectManagementen_US
dc.titleTrends in the choice of antiseizure medications in juvenile myoclonic epilepsy: A retrospective multi-center study from Turkey between 2010 and 2020en_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu